EUVIMEDEUVIMED entdecken
Open Access

Infection-related and Hepatobiliary Death Outcome Reports Involving Avacopan in the Japanese Pharmacovigilance Database

Naohito Ide, Ken-Ichi Sako, Tomoji Maeda

In Vivo · 2026

DOI: 10.21873/invivo.14441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift In Vivo, 2026. Verfasst von Naohito Ide und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Nihon Pharmaceutical University, Saitama, Japan n-ide@nichiyaku.ac.jp. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Infections, Pharmacovigilance. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Avacopan is used to treat antineutrophil cytoplasmic antibody-associated vasculitis. In Japan, serious hepatobiliary adverse events, including vanishing bile duct syndrome, have recently become a major safety concern. This study characterized reports with death recorded as the outcome involving avacopan in the Japanese Adverse Drug Event Report database (JADER). PATIENTS AND METHODS: Reports involving avacopan as a suspected drug and death recorded as the outcome were extracted from JADER. Adverse events were classified by primary system organ class and preferred term. Quarterly reporting trends and time-to-onset were evaluated for hepatobiliary and infection-related adverse events. RESULTS: A total of 79 reports were identified; 64 involved patients aged ≥70 years. Infections and infestations were the most frequent system organ classes among adverse events with death recorded as the outcome (n=46), followed by hepatobiliary disorders (n=21). Vanishing bile duct syndrome was the most frequent hepatobiliary preferred term (n=13). Pneumocystis jirovecii pneumonia and pneumonia were the most frequent infection-related preferred terms (n=9 each). Median time-to-onset was 49 days for hepatobiliary disorders and 75 days for infections and infestations. The proportions of events occurring within 90 days were 94.1% for hepatobiliary disorders and 57.1% for infections and infestations. CONCLUSION: In JADER, death outcome reports involving avacopan frequently included infection-related and hepatobiliary events. Hepatobiliary events occurred mainly within 90 days, whereas infection-related events showed a broader time-to-onset distribution. These findings suggest the need for early hepatobiliary monitoring and continued attention to serious infections during avacopan treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug-Related Side Effects and Adverse ReactionsInfectionsPharmacovigilanceAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdverse Drug Reaction Reporting SystemsDatabases, FactualJapan

Stichwörter der Autor:innen

AvacopanJapanese Adverse Drug Event Report databaseadverse reactionsdeath outcome

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Nihon Pharmaceutical University, Saitama, Japan n-ide@nichiyaku.ac.jp.
  • Department of Clinical Pharmacology, Nihon Pharmaceutical University, Saitama, Japan.

Zitieren

APA

Ide, N., Sako, K. I., & Maeda, T. (2026). Infection-related and Hepatobiliary Death Outcome Reports Involving Avacopan in the Japanese Pharmacovigilance Database. In Vivo. https://doi.org/10.21873/invivo.14441

Vancouver

Ide N, Sako KI, Maeda T. Infection-related and Hepatobiliary Death Outcome Reports Involving Avacopan in the Japanese Pharmacovigilance Database. In Vivo. 2026. doi:10.21873/invivo.14441

BibTeX
@article{Ide2026,
  author = {Ide, Naohito and Sako, Ken-Ichi and Maeda, Tomoji},
  title = {Infection-related and Hepatobiliary Death Outcome Reports Involving Avacopan in the Japanese Pharmacovigilance Database},
  journal = {In Vivo},
  year = {2026},
  doi = {10.21873/invivo.14441}
}
Kostenlos starten →